GLYNASE PRESTAB Rx
Generic Name and Formulations:
Glyburide, micronized 1.5mg, 3mg, 6mg; scored tabs.
Indications for GLYNASE PRESTAB:
Adjunct to diet and exercise in type 2 diabetes.
Initially 1.5–3mg daily with breakfast. Debilitated: initially 0.75mg daily with breakfast. Increase by 1.5mg at weekly intervals if needed per blood glucose. Maintenance: 0.75–12mg daily in single or divided doses (consider divided doses above 6mg daily); max 12mg daily.
Initially 0.75mg daily with breakfast.
Diabetic ketoacidosis, with or without coma. Type 1 diabetes. Concomitant bosentan.
Increased risk of cardiovascular mortality. Impaired renal or hepatic function. Stress. Secondary failure may occur with extended therapy. Discontinue if jaundice or persistent rash occurs. G6PD deficiency; consider non-sulfonylurea alternative. Monitor urine, blood glucose, and glycosylated hemoglobin. Retitrate if transfer from other glyburide containing or hypoglycemic agents (see full labeling). Elderly, debilitated, malnourished, adrenal or pituitary insufficiency, severe/prolonged exercise: increased risk of hypoglycemia. Pregnancy (Cat.B): consider using insulin instead; if glyburide needed, discontinue ≥2 weeks before delivery date. Nursing mothers: not recommended.
Elevated liver enzymes with concomitant bosentan (see Contraindications). Increased risk of hypoglycemia with concomitant alcohol or other hypoglycemics. Potentiated by NSAIDs, alcohol, highly protein bound drugs, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, MAOIs, β-blockers. Antagonized by diuretics, steroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, niacin, sympathomimetics, calcium channel blockers and isoniazid. May be potentiated by ciprofloxacin, oral miconazole. Administer glyburide >4hrs prior to colesevelam. Disulfiram-like reaction with alcohol (rare). Monitor for 2 weeks if transferring from chlorpropamide.
Sulfonylurea (2nd generation).
Hypoglycemia, cholestatic jaundice (rare), nausea, epigastric fullness, heartburn, allergic skin reactions, photosensitivity, blood dyscrasias, hepatic porphyria, hyponatremia.
PresTab 1.5mg—100; 3mg—100, 500, 1000; 6mg—100, 500
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|